Kalaris Therapeutics, Inc. (KLRS)

Price, with every insider trade on it

Closing prices, 12 months · point at a dot for who traded, or at the line for the close

2.36 on 9 Oct 2026

2 buys1 sale at will0 planned sales

Fiscal year 2019, ended 31 Dec 2019, as filed

Revenue

$165.00K

Net income

$23.84M

Free cash flow

$20.49M

Operating margin

-16,182.4%

Net margin

-14,447.9%

Fiscal years, as filed with the SEC · point at a year for the detail

RevenueNet incomeLoss

From Form 4, most recent first

Date	Insider	Type	Value	Of own stake
20 May 2026	AKKARAJU SRINIVAS Director	Bought	$1.18M	12.3%
20 Mar 2026	Hagen Brett R Chief Accounting Officer	Sold at will	$12.87K	100%
18 Dec 2025	AKKARAJU SRINIVAS Director	Bought	$5.00M	32.0%
26 Mar 2025	Hagen Brett R Chief Accounting Officer	Sold at will	$8.14K	32.0%
21 Feb 2025	Sinha Vikas See Remarks	Sold at will	$3.05K	0.6%
21 Feb 2025	Miller Edward General Counsel	Sold at will	$1.07K	1.6%

19out of 100

Profitability 0

Financial strength 17

Growth n/a

Insiders 50

Strongest on insiders (50), weakest on profitability (0). A score of the business, not of the price.

Last 12 months

Only here

Bought

$6.18M

2 buys, 1 buyer

Sold

$12.87K

1 sale

Planned sales

under a 10b5-1 plan